



Figure S3. Upregulation of FUT8 is associated with poor prognosis in breast cancer patients. (A) Kaplan-Meier disease-free survival curves for patients with breast cancer by FUT8-high ($n= 29$) or FUT8-low ($n= 25$) status [1]. (B) Kaplan-Meier distant metastasis-free survival curves for patients with breast cancer by FUT8-high ($n= 67$) or FUT8-low ($n= 69$) status [2]. (C) Kaplan-Meier overall survival curve for patients with breast cancer by FUT8-high ($n= 21$) or FUT8-low ($n= 134$) status [3].

References

- [1] Y. Zhou, C. Yau, J.W. Gray, K. Chew, S.H. Dairkee, D.H. Moore, U. Eppenberger, S. Eppenberger-Castori, C.C. Benz, Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer, *BMC Cancer*, 7 (2007) 59.

[2] Y. Zhang, A.M. Sieuwerts, M. McGreevy, G. Casey, T. Cufer, A. Paradiso, N. Harbeck, P.N. Span, D.G. Hicks, J. Crowe, R.R. Tubbs, G.T. Budd, J. Lyons, F.C. Sweep, M. Schmitt, F. Schittulli, R. Golouh, D. Talantov, Y. Wang, J.A. Foekens, The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy, *Breast Cancer Res. Treat.*, 116 (2009) 303-309.

[3] M. Chanrion, V. Negre, H. Fontaine, N. Salvetat, F. Bibeau, G.M. Grogan, L. Mauriac, D. Katsaros, F. Molina, C. Theillet, J.-M. Darbon, A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer, *Clin. Cancer Res.*, 14 (2008) 1744-1752.